EAGLE, Idaho, Nov. 06, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, today announced its operating results for the third quarter of 2024, reporting GAAP diluted earnings per share of $0.20 for the third quarter of 2024. Pennant also reported adjusted diluted earnings per share of $0.26 for the quarter (1).
Third Quarter Highlights
| (1 | ) | See "Reconciliation of GAAP to Non-GAAP Financial Information.” |
Operating Results
“Our strong third quarter financial results demonstrate the momentum we are building across the business, and we are pleased to see robust performance in our existing operations even as we integrate new ones. The equity offering we executed after quarter end, coupled with the expansion of our revolving credit facility during the quarter, position us exceptionally well for future growth. With these operating results and a healthy balance sheet, we are poised for success through the remainder of 2024 and beyond,” said Brent Guerisoli, the Company’s Chief Executive Officer.
A discussion of the Company's use of Non-GAAP financial measures is set forth below. A reconciliation of net income to EBITDA, adjusted EBITDAR and adjusted EBITDA, as well as a reconciliation of GAAP earnings per share, net income to adjusted net earnings per share and adjusted net income, appear in the financial data portion of this release. More complete information is contained in the Company’s Form 10-Q for the three and nine months ended September 30, 2024, which has been filed with the SEC today and can be viewed on the Company’s website at www.pennantgroup.com.
2024 Guidance
Management is updating its annual guidance as follows: total revenue is anticipated to be between $665.3 million and $706.5 million; full year 2024 adjusted earnings per diluted share is anticipated to be between $0.90 and $0.96; and full year 2024 adjusted EBITDA is anticipated to be between $51.9 million and $55.2 million.
“The Company’s updated guidance reflects the continued momentum in the business, and incorporates current operations and organic growth, diluted weighted average shares outstanding of approximately 32.5 million, and a 26.0% effective tax rate,” stated Lynette Walbom, Pennant’s Chief Financial Officer. “It anticipates consistent operating performance through the end of the year, hospice reimbursement rate adjustments, decreased interest expense, and contributions from our joint ventures and management agreements. It excludes unannounced acquisitions, the announced purchase of Signature’s Oregon assets, start-ups, share-based compensation, acquisition-related costs, or one-time implementation and unusual items.”
Conference Call
A live webcast will be held tomorrow, November 7, 2024 at 10:00 a.m. Mountain time (12:00 p.m. Eastern time) to discuss Pennant’s third quarter 2024 financial results. To listen to the webcast, or to view any financial or statistical information required by SEC Regulation G, please visit the Investors Relations section of Pennant’s website at https://investor.pennantgroup.com. The webcast will be recorded and will be available for replay via the website.
About Pennant
The Pennant Group, Inc. is a holding company of independent operating subsidiaries that provide healthcare services through 122 home health and hospice agencies and 54 senior living communities located throughout Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. Each of these businesses is operated by a separate, independent operating subsidiary that has its own management, employees and assets. References herein to the consolidated "company" and "its" assets and activities, as well as the use of the terms "we," "us," "its" and similar verbiage, are not meant to imply that The Pennant Group, Inc. has direct operating assets, employees or revenue, or that any of the home health and hospice businesses, senior living communities or the Service Center are operated by the same entity. More information about Pennant is available at www.pennantgroup.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains, and the related conference call and webcast will include, forward-looking statements that are based on management’s current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding growth prospects, future operating and financial performance, and acquisition activities. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.
These risks and uncertainties relate to the company’s business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the company’s periodic filings with the Securities and Exchange Commission, including its Form 10-Q and/or 10-K, for a more complete discussion of the risks and other factors that could affect Pennant’s business, prospects and any forward-looking statements. Except as required by the federal securities laws, Pennant does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.
Contact Information
Investor Relations
The Pennant Group, Inc.
(208) 506-6100
This email address is being protected from spambots. You need JavaScript enabled to view it.
| THE PENNANT GROUP, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited, in thousands, except for per-share amounts) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | $ | 180,688 | $ | 140,192 | $ | 506,348 | $ | 398,937 | |||||||
| Expense | |||||||||||||||
| Cost of services | 144,468 | 112,384 | 405,776 | 321,162 | |||||||||||
| Rent—cost of services | 10,906 | 10,006 | 31,814 | 29,439 | |||||||||||
| General and administrative expense | 13,023 | 9,417 | 36,337 | 26,913 | |||||||||||
| Depreciation and amortization | 1,493 | 1,323 | 4,292 | 3,817 | |||||||||||
| Loss (gain) on disposition of property and equipment, net | 4 | 1 | (751 | ) | 4 | ||||||||||
| Total expenses | 169,894 | 133,131 | 477,468 | 381,335 | |||||||||||
| Income from operations | 10,794 | 7,061 | 28,880 | 17,602 | |||||||||||
| Other (expense) income, net: | |||||||||||||||
| Other income (expense) | 109 | (37 | ) | 192 | 28 | ||||||||||
| Interest expense, net | (2,892 | ) | (1,496 | ) | (6,306 | ) | (4,355 | ) | |||||||
| Other expense, net | (2,783 | ) | (1,533 | ) | (6,114 | ) | (4,327 | ) | |||||||
| Income before provision for income taxes | 8,011 | 5,528 | 22,766 | 13,275 | |||||||||||
| Provision for income taxes | 1,354 | 1,066 | 4,957 | 3,894 | |||||||||||
| Net income | 6,657 | 4,462 | 17,809 | 9,381 | |||||||||||
| Less: Net income attributable to noncontrolling interest | 452 | 79 | 1,008 | 351 | |||||||||||
| Net income attributable to The Pennant Group, Inc. | $ | 6,205 | $ | 4,383 | $ | 16,801 | $ | 9,030 | |||||||
| Earnings per share: | |||||||||||||||
| Basic | $ | 0.20 | $ | 0.15 | $ | 0.56 | $ | 0.30 | |||||||
| Diluted | $ | 0.20 | $ | 0.15 | $ | 0.54 | $ | 0.30 | |||||||
| Weighted average common shares outstanding: | |||||||||||||||
| Basic | 30,281 | 29,912 | 30,157 | 29,825 | |||||||||||
| Diluted | 31,363 | 30,206 | 30,869 | 30,178 | |||||||||||
| THE PENNANT GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value) | |||||||
| September 30, 2024 | December 31, 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash | $ | 4,464 | $ | 6,059 | |||
| Accounts receivable—less allowance for doubtful accounts of $313 and $259, respectively | 84,025 | 61,116 | |||||
| Prepaid expenses and other current assets | 13,307 | 12,902 | |||||
| Total current assets | 101,796 | 80,077 | |||||
| Property and equipment, net | 41,865 | 28,598 | |||||
| Right-of-use assets | 265,441 | 262,923 | |||||
| Deferred tax assets, net | 245 | — | |||||
| Restricted and other assets | 12,173 | 9,337 | |||||
| Goodwill | 129,337 | 91,014 | |||||
| Other indefinite-lived intangibles | 95,902 | 67,742 | |||||
| Total assets | $ | 646,759 | $ | 539,691 | |||
| Liabilities and equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 15,888 | $ | 10,841 | |||
| Accrued wages and related liabilities | 36,565 | 28,256 | |||||
| Operating lease liabilities—current | 19,113 | 17,122 | |||||
| Other accrued liabilities | 19,029 | 15,330 | |||||
| Total current liabilities | 90,595 | 71,549 | |||||
| Long-term operating lease liabilities—less current portion | 248,907 | 248,596 | |||||
| Deferred tax liabilities, net | 818 | 1,855 | |||||
| Other long-term liabilities | 10,277 | 8,262 | |||||
| Long-term debt, net | 108,875 | 63,914 | |||||
| Total liabilities | 459,472 | 394,176 | |||||
| Commitments and contingencies | |||||||
| Equity: | |||||||
| Common stock, $0.001 par value; 100,000 shares authorized; 30,565 and 30,308 shares issued and outstanding, respectively, at September 30, 2024; and 30,297 and 29,948 shares issued and outstanding, respectively, at December 31, 2023 | 31 | 29 | |||||
| Additional paid-in capital | 117,947 | 105,712 | |||||
| Retained earnings | 51,464 | 34,663 | |||||
| Treasury stock, at cost, 3 shares at September 30, 2024 and December 31, 2023 | (65 | ) | (65 | ) | |||
| Total The Pennant Group, Inc. stockholders’ equity | 169,377 | 140,339 | |||||
| Noncontrolling interest | 17,910 | 5,176 | |||||
| Total equity | 187,287 | 145,515 | |||||
| Total liabilities and equity | $ | 646,759 | $ | 539,691 | |||
| THE PENNANT GROUP, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) | |||||||
| The following table presents selected data from our condensed consolidated statements of cash flows for the periods presented: | |||||||
| Nine Months Ended September 30, | |||||||
| 2024 | 2023 | ||||||
| Net cash provided by operating activities | $ | 18,729 | $ | 27,910 | |||
| Net cash used in investing activities | (66,287 | ) | (17,576 | ) | |||
| Net cash provided by (used in) financing activities | 45,963 | (9,030 | ) | ||||
| Net (decrease) increase in cash | (1,595 | ) | 1,304 | ||||
| Cash beginning of period | 6,059 | 2,079 | |||||
| Cash end of period | $ | 4,464 | $ | 3,383 | |||
| THE PENNANT GROUP, INC. REVENUE BY SEGMENT (unaudited, dollars in thousands) | |||||||||||||
| The following table sets forth our total revenue by segment and as a percentage of total revenue for the periods indicated: | |||||||||||||
| Three Months Ended September 30, | |||||||||||||
| 2024 | 2023 | ||||||||||||
| Revenue Dollars | Revenue Percentage | Revenue Dollars | Revenue Percentage | ||||||||||
| Home health and hospice services | |||||||||||||
| Home health | $ | 60,988 | 33.8 | % | $ | 44,921 | 32.0 | % | |||||
| Hospice | 62,757 | 34.7 | 50,371 | 35.9 | |||||||||
| Home care and other(a) | 11,927 | 6.6 | 6,182 | 4.4 | |||||||||
| Total home health and hospice services | 135,672 | 75.1 | 101,474 | 72.3 | |||||||||
| Senior living services | 45,016 | 24.9 | 38,718 | 27.7 | |||||||||
| Total revenue | $ | 180,688 | 100.0 | % | $ | 140,192 | 100.0 | % | |||||
| (a | ) | Home care and other revenue is included with home health revenue in other disclosures in this press release. |
| Nine Months Ended September 30, | |||||||||||||
| 2024 | 2023 | ||||||||||||
| Revenue Dollars | Revenue Percentage | Revenue Dollars | Revenue Percentage | ||||||||||
| Home health and hospice services | |||||||||||||
| Home health | $ | 172,773 | 34.1 | % | $ | 129,112 | 32.4 | % | |||||
| Hospice | 176,711 | 34.9 | 140,222 | 35.1 | |||||||||
| Home care and other(a) | 27,979 | 5.5 | 18,239 | 4.6 | |||||||||
| Total home health and hospice services | 377,463 | 74.5 | 287,573 | 72.1 | |||||||||
| Senior living services | 128,885 | 25.5 | 111,364 | 27.9 | |||||||||
| Total revenue | $ | 506,348 | 100.0 | % | $ | 398,937 | 100.0 | % | |||||
| (a | ) | Home care and other revenue is included with home health revenue in other disclosures in this press release. |
| THE PENNANT GROUP, INC. SELECT PERFORMANCE INDICATORS (unaudited, total revenue dollars in thousands) | ||||||||||||||
| The following table summarizes our overall home health and hospice performance indicators for the each of the dates or periods indicated: | ||||||||||||||
| Three Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | Change | % Change | |||||||||||
| Total agency results: | ||||||||||||||
| Home health and hospice revenue | $ | 135,672 | $ | 101,474 | 34,198 | 33.7 | % | |||||||
| Home health services: | ||||||||||||||
| Total home health admissions | 14,993 | 10,829 | 4,164 | 38.5 | % | |||||||||
| Total Medicare home health admissions | 6,071 | 4,640 | 1,431 | 30.8 | % | |||||||||
| Average Medicare revenue per 60-day completed episode(a) | $ | 3,760 | $ | 3,480 | $ | 280 | 8.0 | % | ||||||
| Hospice services: | ||||||||||||||
| Total hospice admissions | 2,987 | 2,433 | 554 | 22.8 | % | |||||||||
| Average daily census | 3,444 | 2,698 | 746 | 27.7 | % | |||||||||
| Hospice Medicare revenue per day | $ | 183 | $ | 183 | $ | — | — | % | ||||||
| Three Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | Change | % Change | |||||||||||
| Same agency(b) results: | ||||||||||||||
| Home health and hospice revenue | $ | 110,748 | $ | 98,732 | $ | 12,016 | 12.2 | % | ||||||
| Home health services: | ||||||||||||||
| Total home health admissions | 12,221 | 10,570 | 1,651 | 15.6 | % | |||||||||
| Total Medicare home health admissions | 5,008 | 4,521 | 487 | 10.8 | % | |||||||||
| Average Medicare revenue per 60-day completed episode(a) | $ | 3,587 | $ | 3,488 | $ | 99 | 2.8 | % | ||||||
| Hospice services: | ||||||||||||||
| Total hospice admissions | 2,624 | 2,351 | 273 | 11.6 | % | |||||||||
| Average daily census | 2,995 | 2,650 | 345 | 13.0 | % | |||||||||
| Hospice Medicare revenue per day | $ | 184 | $ | 186 | $ | (2 | ) | (1.1 | )% | |||||
| Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | Change | % Change | |||||||||||
| Total agency results: | ||||||||||||||
| Home health and hospice revenue | $ | 377,463 | $ | 287,573 | $ | 89,890 | 31.3 | % | ||||||
| Home health services: | ||||||||||||||
| Total home health admissions | 43,782 | 32,180 | 11,602 | 36.1 | % | |||||||||
| Total Medicare home health admissions | 18,155 | 14,437 | 3,718 | 25.8 | % | |||||||||
| Average Medicare revenue per 60-day completed episode(a) | $ | 3,646 | $ | 3,467 | $ | 179 | 5.2 | % | ||||||
| Hospice services: | ||||||||||||||
| Total hospice admissions | 9,118 | 7,206 | 1,912 | 26.5 | % | |||||||||
| Average daily census | 3,209 | 2,544 | 665 | 26.1 | % | |||||||||
| Hospice Medicare revenue per day | $ | 182 | $ | 184 | $ | (2 | ) | (1.1 | )% | |||||
| Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | Change | % Change | |||||||||||
| Same agency(b) results: | ||||||||||||||
| Home health and hospice revenue | $ | 322,941 | $ | 284,228 | $ | 38,713 | 13.6 | % | ||||||
| Home health services: | ||||||||||||||
| Total home health admissions | 36,623 | 31,710 | 4,913 | 15.5 | % | |||||||||
| Total Medicare home health admissions | 15,441 | 14,221 | 1,220 | 8.6 | % | |||||||||
| Average Medicare revenue per 60-day completed episode(a) | $ | 3,546 | $ | 3,469 | $ | 77 | 2.2 | % | ||||||
| Hospice services: | ||||||||||||||
| Total hospice admissions | 7,970 | 7,104 | 866 | 12.2 | % | |||||||||
| Average daily census | 2,851 | 2,528 | 323 | 12.8 | % | |||||||||
| Hospice Medicare revenue per day | $ | 185 | $ | 186 | $ | (1 | ) | (0.5 | )% | |||||
| (a | ) | The year to date average for Medicare revenue per 60-day completed episode includes post period claim adjustments for prior periods. |
| (b | ) | Same agency results represent all agencies purchased or licensed prior to January 1, 2023. |
| The following table summarizes our senior living performance indicators for the periods indicated: | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Total senior living results: | |||||||||||||||
| Senior living revenue | $ | 45,016 | $ | 38,718 | $ | 128,885 | $ | 111,364 | |||||||
| Occupancy | 79.1 | % | 78.9 | % | 78.9 | % | 78.4 | % | |||||||
| Average monthly revenue per occupied unit | $ | 4,836 | $ | 4,486 | $ | 4,758 | $ | 4,401 | |||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Same store senior living(a) results: | |||||||||||||||
| Senior living revenue | $ | 41,030 | $ | 38,126 | $ | 119,625 | $ | 110,225 | |||||||
| Occupancy | 80.2 | % | 80.1 | % | 79.7 | % | 79.6 | % | |||||||
| Average monthly revenue per occupied unit | $ | 4,790 | $ | 4,454 | $ | 4,724 | $ | 4,380 | |||||||
| (a) | Same store senior living results is defined as all senior living communities excluding affiliate memory care units in transition, and new senior living operations acquired in 2023 or 2024. |
| THE PENNANT GROUP, INC. REVENUE BY PAYOR SOURCE (unaudited, dollars in thousands) | ||||||||||||||
| The following table presents our total revenue by payor source as a percentage of total revenue for the periods indicated: | ||||||||||||||
| Three Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Revenue Dollars | Revenue Percentage | Revenue Dollars | Revenue Percentage | |||||||||||
| Revenue: | ||||||||||||||
| Medicare | $ | 86,919 | 48.1 | % | $ | 67,925 | 48.5 | % | ||||||
| Medicaid | 22,715 | 12.6 | 19,893 | 14.2 | ||||||||||
| Subtotal | 109,634 | 60.7 | 87,818 | 62.7 | ||||||||||
| Managed Care | 24,652 | 13.6 | 19,158 | 13.6 | ||||||||||
| Private and Other(a) | 46,402 | 25.7 | 33,216 | 23.7 | ||||||||||
| Total revenue | $ | 180,688 | 100.0 | % | $ | 140,192 | 100.0 | % | ||||||
| (a) | Private and other payors includes revenue from all payors generated in the Company’s home care operations and management services agreement. |
| Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | |||||||||||||
| Revenue Dollars | Revenue Percentage | Revenue Dollars | Revenue Percentage | |||||||||||
| Revenue: | ||||||||||||||
| Medicare | $ | 245,746 | 48.5 | % | $ | 192,895 | 48.3 | % | ||||||
| Medicaid | 66,386 | 13.1 | 56,455 | 14.2 | ||||||||||
| Subtotal | 312,132 | 61.6 | 249,350 | 62.5 | ||||||||||
| Managed Care | 66,084 | 13.1 | 53,538 | 13.4 | ||||||||||
| Private and Other(a) | 128,132 | 25.3 | 96,049 | 24.1 | ||||||||||
| Total revenue | $ | 506,348 | 100.0 | % | $ | 398,937 | 100.0 | % | ||||||
| (a) | Private and other payors includes revenue from all payors generated in the Company’s home care operations and management services agreement. |
| THE PENNANT GROUP, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited, in thousands, except per share data) | |||||||||||||||
| The following table reconciles net income to Non-GAAP net income for the periods presented: | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Net income attributable to The Pennant Group, Inc. | $ | 6,205 | $ | 4,383 | $ | 16,801 | $ | 9,030 | |||||||
| Non-GAAP adjustments | |||||||||||||||
| Costs at start-up operations(a) | 66 | 59 | 244 | 1,060 | |||||||||||
| Share-based compensation expense(b) | 2,342 | 1,391 | 5,817 | 4,164 | |||||||||||
| Acquisition related costs and credit allowances(c) | 494 | 71 | 996 | 175 | |||||||||||
| Interest expense - write off deferred financing fees(e) | 428 | — | 428 | — | |||||||||||
| Costs associated with transitioning operations(d) | 68 | 90 | (418 | ) | 759 | ||||||||||
| Unusual, non-recurring or redundant charges(e) | 239 | 1,009 | 546 | 1,633 | |||||||||||
| Provision for income taxes on Non-GAAP adjustments(f) | (1,675 | ) | (1,031 | ) | (2,942 | ) | (1,562 | ) | |||||||
| Non-GAAP net income | $ | 8,167 | $ | 5,972 | $ | 21,472 | $ | 15,259 | |||||||
| Dilutive Earnings Per Share As Reported | |||||||||||||||
| Net Income | $ | 0.20 | $ | 0.15 | $ | 0.54 | $ | 0.30 | |||||||
| Average number of shares outstanding | 31,363 | 30,206 | 30,869 | 30,178 | |||||||||||
| Adjusted Diluted Earnings Per Share | |||||||||||||||
| Net Income | $ | 0.26 | $ | 0.20 | $ | 0.70 | $ | 0.51 | |||||||
| Average number of shares outstanding | 31,363 | 30,206 | 30,869 | 30,178 | |||||||||||
| (a) | Represents results related to start-up operations. | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||
| Revenue | $ | — | $ | (2,928 | ) | $ | (4,956 | ) | $ | (8,821 | ) | ||||||||
| Cost of services | 65 | 2,820 | 4,884 | 8,981 | |||||||||||||||
| Rent | — | 162 | 306 | 885 | |||||||||||||||
| Depreciation & amortization | 1 | 5 | 10 | 15 | |||||||||||||||
| Total Non-GAAP adjustment | $ | 66 | $ | 59 | $ | 244 | $ | 1,060 | |||||||||||
| (b) | Represents share-based compensation expense incurred for the periods presented. | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||
| Cost of services | $ | 1,069 | $ | 819 | $ | 2,814 | $ | 2,288 | |||||||||||
| General and administrative | 1,273 | 572 | 3,003 | 1,876 | |||||||||||||||
| Total Non-GAAP adjustment | $ | 2,342 | $ | 1,391 | $ | 5,817 | $ | 4,164 | |||||||||||
| (c) | Represents costs incurred to acquire an operation that are not capitalizable. | ||||||||||||||||||
| (d) | During the nine months ended September 30, 2023, an affiliate of the Company placed its memory care units into transition and began seeking to sublease the units to an unrelated third party. The amount above represents the net operating impact attributable to the units in transition. The amounts reported exclude rent and depreciation and amortization expense related to such operations and include legal settlement costs associated with an entity transitioned to Ensign. | ||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||
| Revenue | $ | — | $ | (4 | ) | $ | (1 | ) | $ | (4 | ) | ||||||||
| Cost of services | 12 | 14 | (582 | ) | 599 | ||||||||||||||
| Rent | 53 | 77 | 157 | 156 | |||||||||||||||
| Depreciation | 3 | 3 | 8 | 8 | |||||||||||||||
| Total Non-GAAP adjustment | $ | 68 | $ | 90 | $ | (418 | ) | $ | 759 | ||||||||||
| (e) | Represents unusual or non-recurring charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | ||||||||||||||||||
| (f) | Represents an adjustment to the provision for income tax to the year-to-date effective tax rate of 26.0% and 25.9% for the nine months ended September 30, 2024 and 2023, respectively. This rate excludes the tax benefit of share-based payment awards. | ||||||||||||||||||
| The table below reconciles Consolidated net income to the Consolidated Non-GAAP financial measures, Consolidated Adjusted EBITDA, and to the Non-GAAP valuation measure, Consolidated Adjusted EBITDAR, for the periods presented: | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Consolidated net income | $ | 6,657 | $ | 4,462 | $ | 17,809 | $ | 9,381 | |||||||
| Less: Net income attributable to noncontrolling interest | 452 | 79 | 1,008 | 351 | |||||||||||
| Add: Provision for income taxes | 1,354 | 1,066 | 4,957 | 3,894 | |||||||||||
| Net interest expense | 2,892 | 1,496 | 6,306 | 4,355 | |||||||||||
| Depreciation and amortization | 1,493 | 1,323 | 4,292 | 3,817 | |||||||||||
| Consolidated EBITDA | 11,944 | 8,268 | 32,356 | 21,096 | |||||||||||
| Adjustments to Consolidated EBITDA | |||||||||||||||
| Add: Costs at start-up operations(a) | 65 | (108 | ) | (72 | ) | 160 | |||||||||
| Share-based compensation expense(b) | 2,342 | 1,391 | 5,817 | 4,164 | |||||||||||
| Acquisition related costs and credit allowances(c) | 494 | 71 | 996 | 175 | |||||||||||
| Costs associated with transitioning operations(d) | 12 | 10 | (583 | ) | 595 | ||||||||||
| Unusual, non-recurring or redundant charges(e) | 239 | 1,009 | 546 | 1,633 | |||||||||||
| Rent related to items (a) and (d) above | 53 | 239 | 463 | 1,041 | |||||||||||
| Consolidated Adjusted EBITDA | 15,149 | 10,880 | 39,523 | 28,864 | |||||||||||
| Rent—cost of services | 10,906 | 10,006 | 31,814 | 29,439 | |||||||||||
| Rent related to items (a) and (d) above | (53 | ) | (239 | ) | (463 | ) | (1,041 | ) | |||||||
| Adjusted rent—cost of services | 10,853 | 9,767 | 31,351 | 28,398 | |||||||||||
| Consolidated Adjusted EBITDAR(f) | $ | 26,002 | $ | 70,874 | |||||||||||
| (a) | Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations. | |
| (b) | Share-based compensation expense and related payroll taxes incurred. Share-based compensation expense and related payroll taxes are included in cost of services and general and administrative expense. | |
| (c) | Non-capitalizable costs associated with acquisitions, credit allowances, and write offs for amounts in dispute with the prior owners of certain acquired operations. | |
| (d) | During the nine months ended September 30, 2023, an affiliate of the Company placed its memory care units into transition and began seeking to sublease the units to an unrelated third party. The amount above represents the net operating impact attributable to the units in transition. The amounts reported exclude rent and depreciation and amortization expense related to such operations and include legal settlement costs associated with an entity transitioned to Ensign. | |
| (e) | Represents unusual or non-recurring charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. | |
| (f) | This measure is a valuation measure and is displayed thusly, it is not a performance measure as it excludes rent expense, which is a normal and recurring operating expense and, as such, does not reflect our cash requirements for leasing commitments. Our presentation of Consolidated Adjusted EBITDAR should not be construed as a financial performance measure. |
| The following table present certain financial information regarding our reportable segments. General and administrative expenses are not allocated to the reportable segments and are included in “All Other”: | |||||||||||||||
| Home Health and Hospice Services | Senior Living Services | All Other | Total | ||||||||||||
| Segment GAAP Financial Measures: | |||||||||||||||
| Three Months Ended September 30, 2024 | |||||||||||||||
| Revenue | $ | 135,672 | $ | 45,016 | $ | — | $ | 180,688 | |||||||
| Segment Adjusted EBITDAR from Operations | $ | 23,724 | $ | 13,411 | $ | (11,133 | ) | $ | 26,002 | ||||||
| Three Months Ended September 30, 2023 | |||||||||||||||
| Revenue | $ | 101,474 | $ | 38,718 | $ | — | $ | 140,192 | |||||||
| Segment Adjusted EBITDAR from Operations | $ | 17,271 | $ | 11,473 | $ | (8,097 | ) | $ | 20,647 | ||||||
| Home Health and Hospice Services | Senior Living Services | All Other | Total | ||||||||||||
| Segment GAAP Financial Measures: | |||||||||||||||
| Nine Months Ended September 30, 2024 | |||||||||||||||
| Revenue | $ | 377,463 | $ | 128,885 | $ | — | $ | 506,348 | |||||||
| Segment Adjusted EBITDAR from Operations | $ | 64,488 | $ | 38,226 | $ | (31,840 | ) | $ | 70,874 | ||||||
| Nine Months Ended September 30, 2023 | |||||||||||||||
| Revenue | $ | 287,573 | $ | 111,364 | $ | — | $ | 398,937 | |||||||
| Segment Adjusted EBITDAR from Operations | $ | 47,364 | $ | 33,394 | $ | (23,496 | ) | $ | 57,262 | ||||||
| The table below provides a reconciliation of Segment Adjusted EBITDAR from Operations above to Condensed Consolidated Income from Operations: | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Segment Adjusted EBITDAR from Operations(a) | $ | 26,002 | $ | 20,647 | $ | 70,874 | $ | 57,262 | |||||||
| Less: Depreciation and amortization | 1,493 | 1,323 | 4,292 | 3,817 | |||||||||||
| Rent—cost of services | 10,906 | 10,006 | 31,814 | 29,439 | |||||||||||
| Other income | 109 | (37 | ) | 192 | 28 | ||||||||||
| Adjustments to Segment EBITDAR from Operations: | |||||||||||||||
| Less: Costs at start-up operations(b) | 65 | (108 | ) | (72 | ) | 160 | |||||||||
| Share-based compensation expense(c) | 2,342 | 1,391 | 5,817 | 4,164 | |||||||||||
| Acquisition related costs and credit allowances(d) | 494 | 71 | 996 | 175 | |||||||||||
| Costs associated with transitioning operations(e) | 12 | 10 | (583 | ) | 595 | ||||||||||
| Unusual, non-recurring or redundant charges(f) | 239 | 1,009 | 546 | 1,633 | |||||||||||
| Add: Net income attributable to noncontrolling interest | 452 | 79 | 1,008 | 351 | |||||||||||
| Consolidated Income from Operations | $ | 10,794 | $ | 7,061 | $ | 28,880 | $ | 17,602 | |||||||
| (a) | Segment Adjusted EBITDAR from Operations is net income (loss) attributable to the Company's reportable segments excluding interest expense, provision for income taxes, depreciation and amortization expense, rent, and, in order to view the operations performance on a comparable basis from period to period, certain adjustments including: (1) costs at start-up operations, (2) share-based compensation, (3) acquisition related costs and credit allowances, (4) the costs associated with transitioning operations, (5) unusual, non-recurring or redundant charges, and (6) net income attributable to noncontrolling interest. General and administrative expenses are not allocated to the reportable segments, and are included as “All Other,” accordingly the segment earnings measure reported is before allocation of corporate general and administrative expenses. The Company's segment measures may be different from the calculation methods used by other companies and, therefore, comparability may be limited. | |
| (b) | Represents results related to start-up operations. This amount excludes rent and depreciation and amortization expense related to such operations. | |
| (c) | Share-based compensation expense and related payroll taxes incurred. Share-based compensation expense and related payroll taxes are included in cost of services and general and administrative expense. | |
| (d) | Non-capitalizable costs associated with acquisitions, credit allowances, and write offs for amounts in dispute with the prior owners of certain acquired operations. | |
| (e) | During the nine months ended September 30, 2023, an affiliate of the Company placed its memory care units into transition and began seeking to sublease the units to an unrelated third party. The amount above represents the net operating impact attributable to the units in transition. The amounts reported exclude rent and depreciation and amortization expense related to such operations and include legal settlement costs associated with an entity transitioned to Ensign. | |
| (f) | Represents unusual or non-recurring charges for legal services, implementation costs, integration costs, and consulting fees in general and administrative and cost of services expenses. |
| The tables below reconcile Segment Adjusted EBITDAR from Operations to Segment Adjusted EBITDA from Operations for each reportable segment for the periods presented: | |||||||||||||||
| Three Months Ended September 30, | |||||||||||||||
| Home Health and Hospice | Senior Living | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Segment Adjusted EBITDAR from Operations | $ | 23,724 | $ | 17,271 | $ | 13,411 | $ | 11,473 | |||||||
| Less: Rent—cost of services | 1,861 | 1,439 | 9,045 | 8,567 | |||||||||||
| Rent related to start-up and transitioning operations | — | (72 | ) | (53 | ) | (167 | ) | ||||||||
| Segment Adjusted EBITDA from Operations | $ | 21,863 | $ | 15,904 | $ | 4,419 | $ | 3,073 | |||||||
| Nine Months Ended September 30, | |||||||||||||||
| Home Health and Hospice | Senior Living | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Segment Adjusted EBITDAR from Operations | $ | 64,488 | $ | 47,364 | $ | 38,226 | $ | 33,394 | |||||||
| Less: Rent—cost of services | 5,254 | 4,136 | 26,560 | 25,303 | |||||||||||
| Rent related to start-up and transitioning operations | (122 | ) | (248 | ) | (341 | ) | (793 | ) | |||||||
| Segment Adjusted EBITDA from Operations | $ | 59,356 | $ | 43,476 | $ | 12,007 | $ | 8,884 | |||||||
Discussion of Non-GAAP Financial Measures
EBITDA consists of net income before (a) interest expense, net, (b) (benefits) provisions for income taxes, and (c) depreciation and amortization. Adjusted EBITDA consists of net income attributable to the Company before (a) interest expense, net (b) (benefits) provisions for income taxes, (c) depreciation and amortization, (d) costs incurred for start-up operations, including rent and excluding depreciation, interest and income taxes, (e) share-based compensation expense, (f) non-capitalizable acquisition related costs and credit allowances, (g) net costs associated with transitioning operations, (h) unusual, non-recurring or redundant charges and (i) net income attributable to noncontrolling interest. Consolidated Adjusted EBITDAR is a valuation measure applicable to current periods only and consists of net income attributable to the Company before (a) interest expense, net, (b) (benefits) provisions for income taxes, (c) depreciation and amortization, (d) rent-cost of services, (e) costs incurred for start-up operations, excluding rent, depreciation, interest and income taxes, (f) share-based compensation expense, (g) acquisition related costs and credit allowances, (h) redundant or non-recurring transition services costs, (i) costs associated with transitioning operations, (j) unusual, non-recurring or redundant charges and (j) net income attributable to noncontrolling interest. The company believes that the presentation of EBITDA, adjusted EBITDA, consolidated adjusted EBITDAR, adjusted net income and adjusted earnings per share provides important supplemental information to management and investors to evaluate the company’s operating performance. The company believes disclosure of adjusted net income, adjusted net income per share, EBITDA, adjusted EBITDA and consolidated adjusted EBITDAR has economic substance because the excluded revenues and expenses are infrequent in nature and are variable in nature, or do not represent current revenues or cash expenditures. A material limitation associated with the use of these measures as compared to the GAAP measures of net income and diluted earnings per share is that they may not be comparable with the calculation of net income and diluted earnings per share for other companies in the company's industry. These non-GAAP financial measures should not be relied upon to the exclusion of GAAP financial measures. For further information regarding why the company believes that this non-GAAP measure provides useful information to investors, the specific manner in which management uses this measure, and some of the limitations associated with the use of this measure, please refer to the company's periodic filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Report on Form 10-Q. The company’s periodic filings are available on the SEC's website at www.sec.gov or under the "Financial Information" link of the Investor Relations section on Pennant’s website at http://www.pennantgroup.com.
| Last Trade: | US$30.78 |
| Daily Change: | -1.03 -3.24 |
| Daily Volume: | 282,415 |
| Market Cap: | US$929.860M |
November 01, 2024 September 30, 2024 August 06, 2024 August 01, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
